Lv3
362 积分 2022-11-25 加入
Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE ‐2 trial
3天前
已完结
Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial
3天前
已完结
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
3天前
已完结
Alzheimer’s Drugs Are Finally Tackling the Disease Itself. Here’s How
5天前
已完结
Lecanemab in Early Alzheimer’s Disease
7天前
已完结
Long‐term treatment with ganaxolone for seizures associated with cyclin‐dependent kinase‐like 5 deficiency disorder: Two‐year open‐label extension follow‐up
11天前
已完结
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial
11天前
已完结
Exploring neurodevelopment in CDKL5 deficiency disorder: Current insights and future directions
13天前
已完结
Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study
13天前
已完结
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
14天前
已完结
皖公网安备34019202002308
